AVITA Medical
AVITA Medical's revenue rose 11.4% to $72 million in fiscal 2025. Its operating margin was −59.4%, up from −88.1% a year earlier. Free cash flow was −$32 million. The diluted share count rose 7.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
AVITA Medical lost money in fiscal 2025: a net loss of $49 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 111 | 79 | 89 | 36 | 18 |
| Debt incl. finance leases | — | — | 40 | 42 | 43 |
| Net debt (negative means net cash) | — | — | −49 | 6 | 25 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.8x | 9.4x | — |
| Interest coverage | −1,206.4x | −1,719.1x | −37.3x | −10.6x | −8.5x |
| Current ratio | 16.4x | 8.2x | 7.9x | 2.8x | 0.6x |
| Quick ratio | 16.2x | 8.0x | 7.5x | 2.5x | 0.5x |
Cash flow
Projections
Project AVITA Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $226,654 of AVITA Medical shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Joseph Fralin WoodyDirector | Bought | 10,000 | $4.19 | $41,900 | Form 4 |
| Jun 9, 2026 | Joseph Fralin WoodyDirector | Bought | 5,200 | $4.00 | $20,800 | Form 4 |
| Jun 3, 2026 | Joseph Fralin WoodyDirector | Bought | 10,000 | $4.09 | $40,950 | Form 4 |
| Jun 2, 2026 | Joseph Fralin WoodyDirector | Bought | 10,000 | $4.20 | $41,950 | Form 4 |
| Jun 1, 2026 | Joseph Fralin WoodyDirector | Bought | 10,000 | $4.30 | $43,000 | Form 4 |
| May 20, 2026 | David D O'TooleCFO | Bought | 2,000 | $4.26 | $8,520 | Form 4 |
| May 19, 2026 | David D O'TooleCFO | Bought | 2,000 | $4.24 | $8,480 | Form 4 |
| Mar 11, 2026 | David D O'TooleCFO | Bought | 1,800 | $4.78 | $8,604 | Form 4 |
| Feb 19, 2026 | David D O'TooleCFO | Bought | 3,000 | $4.15 | $12,450 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 9 | 2 of 9 |
| Rule of 40 | −32.9% | −62.3% | −33.5% |
| Altman Z'' | −5.10 | −16.39 | −32.08 |
| Accruals ratio | 2.5% | −13.5% | −25.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | 3 of 9 | 2 of 9 |
Compare
Put AVITA Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| AVITA Medical | FY25 | 11.4% | −59.4% | −45.0% | −354.1% | — | 2 | |
| EDAP TMS | FY25 | 1.6% | −35.0% | — | −83.4% | — | — | Compare |
| Electromed | FY26 | 15.3% | 18.8% | 11.4% | — | — | — | Compare |
| Sight Sciences | FY25 | −3.1% | −48.0% | −38.7% | — | — | 5 | Compare |
| Pro Dex | FY26 | 16.4% | 16.8% | 8.7% | 19.6% | 0.6x | 7 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | 1 | 6 | 14 | 29 | 34 | 50 | 64 | 72 |
| Revenue growth | — | — | 489.2% | 160.6% | 105.0% | 17.8% | 45.7% | 28.1% | 11.4% |
| Gross profit | — | 0 | 4 | 11 | 23 | 28 | 42 | 55 | 59 |
| Research and development | — | 6 | 8 | 9 | 15 | 14 | 21 | 20 | 21 |
| Operating income | — | −14 | −26 | −43 | −26 | −28 | −43 | −57 | −42 |
| Net income | — | −13 | −25 | −42 | −27 | −27 | −35 | −62 | −49 |
| Diluted EPS (US$) | — | — | — | — | — | — | −1.40 | −2.39 | −1.74 |
| Diluted shares (millions) | 670 | 9 | 16 | 20 | 23 | 25 | 25 | 26 | 28 |
| Cash flow | |||||||||
| Cash from operations | — | −13 | −19 | −23 | −26 | −19 | −38 | −49 | −31 |
| Capital expenditure | — | 0 | 1 | 1 | 1 | 0 | 1 | 9 | 1 |
| Free cash flow | — | −13 | −20 | −23 | −27 | −20 | −39 | −58 | −32 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 1 | 2 | 16 | 6 | 7 | 8 | 14 | 10 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 3 | 11 | 20 | 74 | 111 | 79 | 89 | 36 | 18 |
| Debt incl. finance leases | — | — | — | — | — | — | 40 | 42 | 43 |
| Total assets | — | — | 26 | 82 | 126 | 98 | 112 | 80 | 56 |
| Total liabilities | — | — | 5 | 10 | 10 | 13 | 62 | 75 | 73 |
| Shareholders' equity | 4 | 14 | 21 | 72 | 116 | 85 | 49 | 4 | −17 |
| Margins and ratios | |||||||||
| Gross margin | — | 41.2% | 76.8% | 79.2% | 79.7% | 82.5% | 84.5% | 85.8% | 82.1% |
| Operating margin | — | −1,489.9% | −466.4% | −299.2% | −90.8% | −79.9% | −85.1% | −88.1% | −59.4% |
| Net margin | — | −1,370.8% | −458.6% | −294.7% | −90.9% | −77.5% | −70.6% | −96.3% | −67.8% |
| Free cash flow margin | — | −1,434.3% | −370.3% | −163.6% | −91.7% | −56.8% | −78.6% | −90.4% | −45.0% |
| Rule of 40 (growth + FCF margin) | — | — | 118.9% | −3.1% | 13.3% | −39.0% | −32.9% | −62.3% | −33.5% |
| Return on capital | — | — | — | — | — | — | — | — | −354.1% |
| Return on equity | — | — | — | −90.2% | −28.3% | −26.6% | −52.9% | −231.0% | — |
| Return on assets | — | — | — | −77.7% | −25.6% | −23.8% | −33.7% | −64.6% | −71.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |